Enlivex, a Nasdaq-listed biotechnology company, is asking shareholders to authorize up to $800 million of financing tied to the RAIN crypto token. The structure could increase its share count by as much as 951%.
Despite Enlivex’s biotech business, the financing is primarily a crypto-treasury transaction. RAIN delivered at closing would go to the company’s treasury wallets, while substantially all cash or stablecoin proceeds are earmarked to acquire the token or support other treasury purposes, transaction costs, and debt. Only up to 5% of remaining USD proceeds could fund Allocetra.
Shareholder approval is required for an initial $400 million placement and the maximum securities available under a separate, company-controlled $400 million option. The first tranche alone could equal roughly four to five times Enlivex’s latest disclosed shares outstanding.
Enlivex said in a Form 6-K that it would use commercially reasonable efforts to call and hold the meeting within 60 days of its July 27 agreement.
Under the securities purchase agreement, the investor elected to pay in the RAIN token but can change that choice before closing. RAIN consideration carries a $6 total price per ordinary-share equivalent, while USD, USDT, or USDC carries a $5 price.
The public documents do not clearly identify the buyer. The 6-K calls it Rain Foundation, while the agreement defines Token Factor Foundation as the lead investor and leaves the public purchaser signature block blank. The filings do not establish whether the two names refer to the same entity.
Dilution depends on the payment method
If the first tranche is paid entirely in RAIN, it represents about 66.7 million ordinary shares or underlying pre-funded-warrant shares. Payment entirely in cash or stablecoins would represent 80 million. Enlivex said in a July 7 filing that its 1-for-15 reverse split would reduce issued and outstanding shares to approximately 16.83 million.
The initial issuance therefore equals about 396% of that baseline at the RAIN price or 475% at the cash-like price. On a share-equivalent basis, current holders would account for roughly 20.2% or 17.4% of the enlarged total, respectively.
The comparison uses issued and outstanding shares because the filings provide no current fully diluted count. Enlivex’s latest detailed option and warrant table is dated Dec. 31, 2025, while a later Lind financing allows variable share issuance, so those historical figures cannot safely be combined with the July count.
Full use of the optional second tranche under one payment method would lift total new share equivalents to about 133.3 million at the RAIN price or 160 million at the cash-like price. That is roughly 792% or 951% of the current outstanding baseline, leaving existing holders at about 11.2% or 9.5% of the resulting share-equivalent total.
Pre-funded warrants do not remove that overhang. They are immediately exercisable and do not expire, although beneficial-ownership limits can delay exercise.
The vote must cover securities for both the initial closing and the maximum put under Israeli law and Nasdaq rules. After closing, Enlivex may compel the lead investor to buy up to another $400 million of shares or pre-funded warrants over as long as 36 months. The investor cannot demand that second purchase, and Enlivex is not guaranteed the additional proceeds.
The proceeds favor RAIN over Allocetra
Substantially all net proceeds paid in USD, USDT, or USDC are earmarked for acquiring RAIN, other treasury purposes, transaction costs, and outstanding debt. Only up to 5% of USD net proceeds remaining after fees, expenses, and debt may fund Allocetra. RAIN delivered at closing goes to the company treasury wallets.
RAIN quantity will be set from CoinMarketCap’s average closing price over the five business days before closing. That calculation does not establish realizable cash value. CryptoSlate’s point-in-time RAIN market page showed about $29.88 million in 24-hour reported volume, making $400 million roughly 13.4 times one day’s turnover. Reported volume is not executable liquidity.